INTRODUCTION
CA 125 is the cell surface antigen expressed by derivatives of coelomic and müllerian epithelia, including endocervix, endometrium, Fallopian tubes, peritoneum, pleura, and pericardium. Increased serum levels of CA 125 were first detected in patients with invasive epithelial ovarian cancer. Successively, elevated CA 125 levels were also observed in the serum, menstrual effluent, and peritoneal fluid of women with endometriosis (1, 2) . However, the sensitivity of serum CA 125 assessment is too low for it to be used as a screening or diagnostic test for endometriosis (3) . Despite the poor sensitivity, it has been reported that the degree of elevation is related to the severity of endometriosis (2) . The combination of elevated serum CA 125 with positive clinical findings (detection of pelvic nodularity) improves the diagnostic power of this test, reaching a sensitivity of 87% (4).
In the present study we evaluate whether serum CA 125 levels correlate with the Revised American Fertility Society (R-AFS) classification and whether serum CA 125 measurement should be performed in the routine workup for dysmenorrhea and dyspareunia. The correlation between symptoms and serum CA 125 levels in pa-tients with endometriosis has not been thoroughly investigated.
MATERIALS AND METHODS
A total of 86 patients participated in the study, 69 had endometriosis and 17 did not; the latter group served as control group. The mean (±SD) age of the 86 patients was 33.6 (±7.3) years (range 21-54 years). The mean ages were 33.6 (±3.2) years for patients without endometriosis and 35.2 (±7.1) years for those with endometriosis. There was no significant difference in age between the 2 groups. We recruited patients with endometriosis who underwent laparoscopy with a preoperative diagnosis of infertility, ovarian cysts or endometriosis and excluded any patients with malignant tumors or inflammatory disease. In all of the patients, endometriosis was diagnosed and classified into stages according to the R-AFS classification: 6 patients presented with stage I, 8 with stage II, 28 with stage III, and 27 with stage IV disease (Tab. II). The 17 control patients underwent laparoscopy in the same hospital with a preoperative diagnosis of ovarian cysts and were confirmed to have no endometriosis.
Preoperative blood samples to measure serum CA 125 were taken in the follicular phase of the menstrual cycle after the end of the menstrual period. The serum CA 125 levels were measured by enzyme immunoassay and were expressed in arbitrary units based on a primary reference standard. In this study, we chose 35.0 U/mL as the cutoff value for serum CA 125 levels.
To determine the clinical value of the CA 125 test for the diagnosis of endometriosis, the parameters of the test, i.e., sensitivity, specificity and positive and negative predictive value, were calculated by JavaStat 2-way contingency table analysis.
We also investigated the relationship between serum CA 125 levels and the intensity of dysmenorrhea and dyspareunia symptoms. A structured questionnaire including an evaluation of the dysmenorrhea and dyspareunia with a 10-point linear analog scale (LAS), 0 representing absence of pain and 10 representing the worst possible pain, was given to all women with endometriosis.
Statistical analysis of the differences between the mean serum CA 125 levels in various groups was performed by an unpaired t-test, and an analysis of the percentage of patients with abnormally elevated values was performed by the chi-square test. P<0.05 was considered statistically significant.
RESULTS
The sensitivity, specificity, positive and negative predictive values for the diagnosis of endometriosis in the evaluated patient series are shown in Table I . In this study the sensitivity and specificity of the CA 125 test for the diagnosis of endometriosis were 0.67 and 0.94, respectively, in stages I-IV. However, if we consider only stages I-II, the sensitivity was 0.47 and the specificity 0.94; if we consider stages III-IV, the sensitivity was 0.76 and the specificity 0.94 (Tab. I). Table II shows the mean serum CA 125 levels and the percentage of patients with abnormally elevated values in various stages of endometriosis according to the R-AFS classification. The mean CA 125 levels in patients at stages I, II, III and IV were significantly elevated (p<0.05) compared with the mean level in the control patients without endometriosis; however, the mean CA 125 level in patients at stage I of endometriosis was not significantly higher than that of controls (p=0.08). The mean CA 125 levels in patients at stages III and IV of endometriosis were significantly elevated (p<0.05) compared with those of patients at stages I and II (p<0.05). In the study group (endometriosis) 52% (36/69) of patients had dysmenorrhea, 26% (18/69) had dyspareunia, and 22% (15/69) were asymptomatic. The percentage of patients with serum levels of CA 125 >35 U/mL tended to be increased, although without reaching statistical significance, in the subgroups with severe dyspareunia (87.5%, 95% confidence interval (CI): 79,7-95,7 and se-vere dysmenorrhea (69.2%, 95% CI: 58,5-79,9) compared to asymptomatic patients (64.7%, 95% CI: 53,6-75,8).
DISCUSSION
The sensitivity of serum CA 125 measurement in the diagnosis of endometriosis varies in the literature between 0.04 and 1.0, and the specificity varies between 0.38 and 1 (5) .
In this study the sensitivity and specificity of the CA 125 test for the diagnosis of endometriosis were 0.67 and 0.95, respectively, in stages I-IV. However, if we consider only stages I-II, the sensitivity was 0.47 and the specificity 0.94; if we consider stages III-IV, the sensitivity was 0.76 and the specificity 0.94. Therefore, the capacity of serum CA 125 measurement in the diagnosis of stage III-IV endometriosis was better than in any stage of endometriosis. This is consistent with the findings of Harada et al, who reported that measurement of serum CA 19.9 as well as serum CA 125 may prove to be a valuable tool for predicting the severity of endometriosis as diagnosed by laparoscopy (6) .
Endometriosis should be suspected when dysmenorrhea, dyspareunia, or chronic pelvic pain is present (5) . However, in this study no statistically significant correlation was found between serum CA 125 levels and the intensity of dysmenorrhea and dyspareunia. The correlation between symptoms and serum CA 125 levels in patients with endometriosis has not been thoroughly investigated, and further studies are therefore necessary.
In conclusion, the performance of serum CA 125 measurement for the detection of any type of endometriosis was rather poor, but it was better for the detection of severe endometriosis. No correlation was found between serum levels of CA 125 and pelvic pain in patients with endometriosis. However, unlike laparoscopy, serum CA 125 measurement is a relatively in-expensive, minimally invasive test. Therefore, in patients with chronic pelvic pain or infertility CA125 could be proposed as a first-line routine test to select patients for laparoscopy.
